KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial.

Mark A Socinski, Rolf Stahel, Dae Ho Lee, Federico Cappuzzo, Makoto Nishio, Christine M Lovly, Ozgur Ozyilkan, Qingshan Li, Melissa Johnson, Edward B Garon, Saadettin Kilickap, Flavio Augusto Ferreira da Silva, Jorge Alatorre-Alexander, Raymond Meng, Reena Amin, Christina Matheny, Sarah Troutman, Xiaohui Wen, Namrata S Patil, Wei Zou, Delvys Rodriguez-Abreu

JAMA Oncol 12(6) 619-627

PMID42060297
PMCIDPMC13133723
DOI10.1001/jamaoncol.2026.0818
发表日期2026-04-30
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

IMPORTANCE: Programmed cell death 1 ligand 1/programmed cell death protein 1 inhibitors, with or without chemotherapy, are standard first-line treatment for patients with advanced non-small cell lung cancer (NSCLC); however, survival benefit is limited, and many patients experience disease progression. OBJECTIVE: To evaluate the efficacy and safety of tiragolumab plus atezolizumab plus chemotherapy vs placebo plus pembrolizumab plus chemotherapy in patients with advanced nonsquamous NSCLC. DESIGN, SETTING, AND PARTICIPANTS: SKYSCRAPER-06 was a phase 3 randomized clinical trial that recruited patients with previously untreated, locally advanced unresectable or metastatic NSCLC at 129 sites in 21 countries between December 15, 2020, and September 14, 2023 (data cutoff, April 19, 2024). INTERVENTION: Patients were randomized 1:1 to receive either tiragolumab, 600 mg, plus atezolizumab, 1200 mg, plus chemotherapy (pemetrexed, 500 mg/m2, and carboplatin [area under the curve 5], or cisplatin, 75 mg/m2) or placebo plus pembrolizumab, 200 mg, plus chemotherapy via intravenous infusion on day 1 of each 21-day cycle until disease progression, loss of clinical benefit, unacceptable toxic effect, or withdrawal of consent. MAIN OUTCOMES AND MEASURES: Primary end points were investigator-assessed progression-free survival and overall survival. The safety and tolerability of the study drugs were also evaluated. RESULTS: Of 542 patients in the full analysis set (mean [SD] age, 63.6 [9.3] years; 353 [65.1%] male), 269 were randomized to tiragolumab plus atezolizumab plus chemotherapy and 273 to placebo plus pembrolizumab plus chemotherapy. Overall, baseline demographics were similar between treatment groups. At data cutoff (median follow-up, 11.8 months), median investigator-assessed progression-free survival was 8.3 months (95% CI, 7.1-9.6 months) with tiragolumab plus atezolizumab plus chemotherapy vs 9.9 months (95% CI, 8.7-11.9 months) with placebo plus pembrolizumab plus chemotherapy (hazard ratio, 1.27; 95% CI, 1.02-1.57; P = .99); median overall survival was 18.9 months (95% CI, 15.2-23.8 months) vs 23.1 months (95% CI, 20.7-33.0 months) in each treatment group, respectively (hazard ratio, 1.33; 95% CI, 1.02-1.73; P = .98). Grade 3 to 4 adverse events occurred in 164 of 267 patients (61.4%) in the tiragolumab plus atezolizumab plus chemotherapy group and 165 of 272 patients (60.7%) in the placebo plus pembrolizumab plus chemotherapy group, with grade 5 AEs occurring in 27 of 267 patients (10.1%) and 16 of 272 patients (5.9%) in each group, respectively. CONCLUSIONS AND RELEVANCE: In the phase 3 SKYSCRAPER-06 randomized clinical trial, the primary end points were not met and the study has been terminated. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04619797.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Figure 2

Figure 2.. Kaplan-Meier Curves of Investigator-Assessed Progression-Free Survival and Overall Survival in the Full Analysis Set NE indicates not estimable.

A

Progression-free survival

Figure 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

Overall survival

Figure 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1.. CONSORT Diagram PD-L1 indicates programmed cell death 1 ligand 1. a In the tiragolumab plus atezolizumab plus chemotherapy group, there were 3 patients who discontinued tiragolumab for other reasons, and 2 patients who discontinued atezolizumab for other reasons.
非 KM Figure